Condition: T-cell Lymphoma · Cutaneous/Peripheral T-Cell Lymphoma · Peripheral T-cell Lymphoma · Sponsor: SciTech Development, Inc.
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
This description comes directly from the study's public registry record.
Louis M Scarmoutzos, PhD · (617) 283-2182 · lou@scitechdevelopment.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Arizona | Scottsdale, Arizona, United States | Recruiting |
| City of Hope Medical Foundation | Duarte, California, United States | Recruiting |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| University of Colorado Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Northwestern University, Robert H. Lurie Comprehensive Cancer Center | Chicago, Illinois, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Barbara Ann Karmanos Cancer Institute Wayne State University | Detroit, Michigan, United States | Recruiting |
| Columbia University | New York, New York, United States | Recruiting |
| University of Pittsburgh Medical Center (UPMC) | Pittsburgh, Pennsylvania, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04234048